Skip to content

Study · Not a test of the peptide alone · 1992

6 results

[Thymogen in the complex treatment of inflammatory diseases of the female genital system].

Tsvelev IuV, Khavinson VKh, Diachuk AV, Gur'ev AV, Seryĭ SV

Akusherstvo i ginekologiia1 Feb 1992

PMID1476231 (opens in a new tab)PepBankPUB-01476231
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymogen (oglufanide).

  1. 01HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In patients with female genital inflammation, combined therapy with thymogen contributed to normalization of lymphocyte counts.

    In plain wordsIn patients with female genital inflammation, combined therapy with thymogen contributed to normalization of lymphocyte counts.

    Peptide
    Thymogen (oglufanide)
    Outcome
    Not applicableLymphocyte counts
    Study

    n = 46

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Thymogen therapy was conducive to normalization of lymphocyte counts, absolute counts of T and B lymphocytes, increase of T lymphocyte functional activity.
    1 context sentence
    Summary · context
    Thymogen, a new immunomodulating drug made in this country, was used in combined therapy of 46 patients with acute endomyometritis, exacerbations of chronic salpingo-oophoritis, purulent tubo-ovarian formations.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  2. 02HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In patients with female genital inflammation, combined therapy with thymogen contributed to normalization of absolute T lymphocyte counts.

    In plain wordsIn patients with female genital inflammation, combined therapy with thymogen contributed to normalization of absolute T immune cell counts.

    Peptide
    Thymogen (oglufanide)
    Outcome
    Not applicableAbsolute T lymphocyte counts
    Study

    n = 46

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Thymogen therapy was conducive to normalization of lymphocyte counts, absolute counts of T and B lymphocytes, increase of T lymphocyte functional activity.
    1 context sentence
    Summary · context
    Thymogen, a new immunomodulating drug made in this country, was used in combined therapy of 46 patients with acute endomyometritis, exacerbations of chronic salpingo-oophoritis, purulent tubo-ovarian formations.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  3. 03HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In patients with female genital inflammation, combined therapy with thymogen contributed to normalization of absolute B lymphocyte counts.

    In plain wordsIn patients with female genital inflammation, combined therapy with thymogen contributed to normalization of absolute B immune cell counts.

    Peptide
    Thymogen (oglufanide)
    Outcome
    Not applicableAbsolute B lymphocyte counts
    Study

    n = 46

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Thymogen therapy was conducive to normalization of lymphocyte counts, absolute counts of T and B lymphocytes, increase of T lymphocyte functional activity.
    1 context sentence
    Summary · context
    Thymogen, a new immunomodulating drug made in this country, was used in combined therapy of 46 patients with acute endomyometritis, exacerbations of chronic salpingo-oophoritis, purulent tubo-ovarian formations.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  4. 04HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In patients with female genital inflammation, combined therapy with thymogen increased T lymphocyte functional activity.

    In plain wordsIn patients with female genital inflammation, combined therapy with thymogen increased T immune cell activity.

    Peptide
    Thymogen (oglufanide)
    Outcome
    IncreaseT lymphocyte functional activity
    Study

    n = 46

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Thymogen therapy was conducive to normalization of lymphocyte counts, absolute counts of T and B lymphocytes, increase of T lymphocyte functional activity.
    1 context sentence
    Summary · context
    Thymogen, a new immunomodulating drug made in this country, was used in combined therapy of 46 patients with acute endomyometritis, exacerbations of chronic salpingo-oophoritis, purulent tubo-ovarian formations.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  5. 05HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In patients with female genital inflammation, the abstract reports a desensitizing effect during combined therapy with thymogen.

    In plain wordsIn patients with female genital inflammation, the abstract reports a desensitizing effect during combined therapy with thymogen.

    Peptide
    Thymogen (oglufanide)
    Outcome
    Not applicableDesensitizing effect
    Study

    n = 46

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The drug is characterized by a desensitizing effect and induces no complications.
    1 context sentence
    Summary · context
    Thymogen, a new immunomodulating drug made in this country, was used in combined therapy of 46 patients with acute endomyometritis, exacerbations of chronic salpingo-oophoritis, purulent tubo-ovarian formations.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  6. 06HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialSafety outcome

    In patients with female genital inflammation, the abstract reports no complications during combined therapy with thymogen.

    In plain wordsIn patients with female genital inflammation, the abstract reports no complications during combined therapy with thymogen.

    Peptide
    Thymogen (oglufanide)
    Outcome
    Not applicableComplications
    Study

    n = 46

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    The drug is characterized by a desensitizing effect and induces no complications.
    1 context sentence
    Summary · context
    Thymogen, a new immunomodulating drug made in this country, was used in combined therapy of 46 patients with acute endomyometritis, exacerbations of chronic salpingo-oophoritis, purulent tubo-ovarian formations.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.